Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
Casiraghi M, Maisonneuve P, Piperno G, Bellini R, Brambilla D, Petrella F, Marinis F, Spaggiari L. Casiraghi M, et al. Among authors: marinis f. Semin Thorac Cardiovasc Surg. 2017 Summer;29(2):233-241. doi: 10.1053/j.semtcvs.2017.02.001. Epub 2017 Feb 24. Semin Thorac Cardiovasc Surg. 2017. PMID: 28823336
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK. Marinis F, et al. Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24. Future Oncol. 2019. PMID: 31339357
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. Nagasaka M, et al. Among authors: marinis f. Future Oncol. 2023 Jan;19(2):123-135. doi: 10.2217/fon-2022-1059. Epub 2023 Mar 6. Future Oncol. 2023. PMID: 36877099
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Solomon BJ, Liu G, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: marinis f. Future Oncol. 2024 Oct 3:1-11. doi: 10.1080/14796694.2024.2406117. Online ahead of print. Future Oncol. 2024. PMID: 39360949
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Solomon BJ, Bauer TM, K Mok TS, Liu G, Mazieres J, Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: marinis f. Future Oncol. 2023 May;19(14):961-973. doi: 10.2217/fon-2022-1289. Epub 2023 Jun 12. Future Oncol. 2023. PMID: 37306090 Review.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Cheema P, Cho BC, Freitas H, Provencio M, Chen YM, Kim SW, Wu YL, Passaro A, Martin C, Tiseo M, Chang GC, Park K, Solomon B, Burghuber O, Laskin J, Wang Z, Lee SY, Hu Y, Vansteenkiste J, Zhang HL, Hanrahan E, Geldart T, Taylor R, Servidio L, Li J, Marinis F. Cheema P, et al. Among authors: marinis f. Future Oncol. 2023 Jan;19(1):61-75. doi: 10.2217/fon-2022-0919. Epub 2023 Jan 19. Future Oncol. 2023. PMID: 36656302
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
Reck M, Granados ALO, de Marinis F, Meyers O, Shen Q, Cho L, Stjepanovic N, Boklage S. Reck M, et al. Among authors: de marinis f. Eur J Cancer. 2024 Nov;212:115050. doi: 10.1016/j.ejca.2024.115050. Epub 2024 Sep 29. Eur J Cancer. 2024. PMID: 39378565 Clinical Trial.
391 results